Simona Mattiussi

Dr. Simona Mattiussi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSimona Mattiussi
Simona Mattiussi
MHMatthias M. Herth
Matthias M. Herth
UBUmberto Maria Battisti
Umberto Maria Battisti
Targeted radioligand therapy (TRT) delivers radionuclides systemically via tumor-specific ligands, allowing precise tumor targeting with minimal impact on healthy tissue (unlike conventional radiotherapy, which directs external radiation beams at tumors and can affect surrounding normal tissue). Increasing evidence highlights the tumor microenvironment (TME) as a promising therapeutic target, with cancer-associated fibroblasts (CAFs) playing a central role in tumor progression through angiogenesis, immune suppression, and extracellular matrix remodeling. CAFs are defined by expression of fibroblast activation protein (FAP), present in most epithelial cancers but rare in normal tissues, making FAP an attractive, broadly applicable target. Small-molecule FAP inhibitors (FAPIs), particularly derivatives of the quinoline scaffold UAMC1110, have shown high affinity and specificity. Several 68Ga-labeled FAPI tracers, such as FAPI-04 and FAPI-46, are under clinical evaluation and demonstrate high tumor-to-background ratios, outperforming [18F]FDG in various cancer types (especially in low-glucose-avid tumors). Their favorable biodistribution and potential for theranostic pairing highlights their clinical promise. However, current FAPI-based agents exhibit insufficient tumor retention for therapeutic applications with long-lived radionuclides commonly used in radioligand therapy (e.g., 177Lu, 131I, or 225Ac), as the FAPi ligand's rapid clearance limits effective radiation delivery. To enable effective clinical translation of targeted radiotherapy, optimizing pharmacokinetics is critical, prolonging tumor residence time while accelerating clearance from non-target tissues to minimize off-target radiation exposure. This review summarizes current progress in FAP-targeted radiopharmaceuticals and outlines strategies to enhance their therapeutic applicability through different strategies that lead to prolonged tumor retention.

13 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
JMJulie van Krimpen Mortensen
Julie van Krimpen Mortensen
SMSimona Mattiussi
Simona Mattiussi
LHLars Hvass
Lars Hvass
ELEmilie Graae Lund
Emilie Graae Lund
VSVladimir Shalgunov
Vladimir Shalgunov
Andreas KjaerAndreas Kjaer
Andreas Kjaer
The use of fibroblast activation protein inhibitors (FAPis) for positron emission tomography (PET) imaging in cancer has garnered significant interest in recent years, yielding promising results in preclinical and clinical settings. FAP is predominantly expressed in pathological conditions such as fibrosis and cancer, making it a compelling target. An optimized approach involves using FAPi homodimers as PET tracers, which enhance tumor uptake and retention, making them more effective candidates for therapy. Here, a UAMC-1110 inhibitor-based homodimer, DOTAGA-Glu(FAPi)2, was synthesized and radiolabeled with gallium-68, and its efficacy was evaluated in vivo for PET imaging in an endogenously FAP-expressing xenografted mouse model, U87MG. Notably, 45 min post-injection, the mean uptake of [68Ga]Ga-DOTAGA-Glu(FAPi)2 was 4.7 ± 0.5% ID/g in the tumor with low off-target accumulation. The ex vivo analysis of the FAP expression in the tumors confirmed the in vivo results. These findings highlight and confirm the tracer’s potential for diagnostic imaging of cancer and as a theranostic companion.